|
EP1471152A1
(en)
|
2003-04-25 |
2004-10-27 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Mutations in the human PCSK9 gene associated to hypercholesterolemia
|
|
KR100985090B1
(ko)
|
2008-05-23 |
2010-10-04 |
한국과학기술연구원 |
크라이센 노출 여부 확인용 바이오마커 및 이를 이용한확인 방법
|
|
JP5703218B2
(ja)
|
2008-08-14 |
2015-04-15 |
ネステク ソシエテ アノニム |
満腹感、脂質代謝及び脂肪利用に影響を及ぼすための組成物及び方法
|
|
EP2488663A4
(en)
|
2009-10-16 |
2012-09-05 |
Genetics Invest Pty Ltd |
SENSITIVITY TO MACRONUTRIENT
|
|
WO2012048414A1
(en)
|
2010-10-12 |
2012-04-19 |
Mcmaster University |
A method of regulating plasma lipoproteins
|
|
WO2013043041A2
(en)
|
2011-09-21 |
2013-03-28 |
Infovalley® Group Of Companies |
Methods and compositions for diagnosing familial hypercholesterolemia
|
|
US20150140005A1
(en)
*
|
2012-05-17 |
2015-05-21 |
Cyon Therapeutics Inc. |
Methods and Uses for Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Inhibitors
|
|
WO2014028946A2
(en)
|
2012-08-17 |
2014-02-20 |
The Broad Institute, Inc. |
Modulators of hepatic lipoprotein metabolism
|
|
TWI682780B
(zh)
|
2013-05-30 |
2020-01-21 |
美商再生元醫藥公司 |
醫藥組成物用於製造治療與ｐｃｓｋ９功能獲得性突變有關之體染色體顯性高膽固醇血症的藥物之用途
|
|
EP3052521A1
(en)
*
|
2013-10-03 |
2016-08-10 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding low density lipoprotein receptor
|
|
WO2015073709A2
(en)
|
2013-11-14 |
2015-05-21 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Detection of atherosclerotic cardiovascular disease risk and heart failure risk
|
|
WO2015073710A2
(en)
|
2013-11-14 |
2015-05-21 |
THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTEMENT OF HEALTH AND HUMAN SERVICES |
Detection of atherosclerotic cardiovascular disease risk and myocardial infarction risk
|
|
US9023359B1
(en)
|
2014-07-15 |
2015-05-05 |
Kymab Limited |
Targeting rare human PCSK9 variants for cholesterol treatment
|
|
US9067998B1
(en)
|
2014-07-15 |
2015-06-30 |
Kymab Limited |
Targeting PD-1 variants for treatment of cancer
|
|
US9034332B1
(en)
|
2014-07-15 |
2015-05-19 |
Kymab Limited |
Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
|
|
US8945560B1
(en)
|
2014-07-15 |
2015-02-03 |
Kymab Limited |
Method of treating rheumatoid arthritis using antibody to IL6R
|
|
US8986694B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Targeting human nav1.7 variants for treatment of pain
|
|
WO2015092393A2
(en)
|
2013-12-17 |
2015-06-25 |
Kymab Limited |
Human targets
|
|
US8883157B1
(en)
|
2013-12-17 |
2014-11-11 |
Kymab Limited |
Targeting rare human PCSK9 variants for cholesterol treatment
|
|
US8992927B1
(en)
|
2014-07-15 |
2015-03-31 |
Kymab Limited |
Targeting human NAV1.7 variants for treatment of pain
|
|
US9051378B1
(en)
|
2014-07-15 |
2015-06-09 |
Kymab Limited |
Targeting rare human PCSK9 variants for cholesterol treatment
|
|
US9045545B1
(en)
|
2014-07-15 |
2015-06-02 |
Kymab Limited |
Precision medicine by targeting PD-L1 variants for treatment of cancer
|
|
US8986691B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
|
US9045548B1
(en)
|
2014-07-15 |
2015-06-02 |
Kymab Limited |
Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
|
|
US8980273B1
(en)
|
2014-07-15 |
2015-03-17 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
|
US9017678B1
(en)
|
2014-07-15 |
2015-04-28 |
Kymab Limited |
Method of treating rheumatoid arthritis using antibody to IL6R
|
|
US9914769B2
(en)
|
2014-07-15 |
2018-03-13 |
Kymab Limited |
Precision medicine for cholesterol treatment
|
|
CA2947127A1
(en)
|
2014-05-02 |
2015-11-19 |
Cerenis Therapeutics Holding Sa |
Hdl therapy markers
|
|
EP4328245A3
(en)
|
2014-07-15 |
2024-06-05 |
Kymab Ltd. |
Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations
|
|
US9139648B1
(en)
|
2014-07-15 |
2015-09-22 |
Kymab Limited |
Precision medicine by targeting human NAV1.9 variants for treatment of pain
|
|
US9150660B1
(en)
|
2014-07-15 |
2015-10-06 |
Kymab Limited |
Precision Medicine by targeting human NAV1.8 variants for treatment of pain
|
|
WO2016023916A1
(en)
|
2014-08-12 |
2016-02-18 |
Kymab Limited |
Treatment of disease using ligand binding to targets of interest
|
|
WO2016071701A1
(en)
|
2014-11-07 |
2016-05-12 |
Kymab Limited |
Treatment of disease using ligand binding to targets of interest
|
|
NL2014136B1
(en)
|
2015-01-14 |
2017-01-27 |
Stichting Katholieke Univ |
Annexin A2 SNP and von Willebrand Disease.
|
|
US10265379B2
(en)
|
2015-09-16 |
2019-04-23 |
Annabelle Rodriguez Oquendo |
Use of recombinant lymphocyte activation gene-3 as a companion therapeutic for patients at risk for cardiovascular disease and other chronic inflammatory diseases
|
|
WO2017218798A1
(en)
|
2016-06-15 |
2017-12-21 |
Boston Heart Diagnostics |
Systems and methods for diagnosing familial hypercholesterolemia
|
|
ES2871783T3
(es)
*
|
2016-09-20 |
2021-11-02 |
Univ Aarhus |
Compuestos para el tratamiento de trastornos del metabolismo de las lipoproteínas
|
|
US10337070B2
(en)
|
2017-01-12 |
2019-07-02 |
Cardioforecast Ltd. |
Methods and kits for treating cardiovascular disease
|
|
US20190345557A1
(en)
|
2017-07-12 |
2019-11-14 |
The General Hospital Corporation |
Atrial fibrillation polygenic risk score
|
|
US20190017119A1
(en)
|
2017-07-12 |
2019-01-17 |
The General Hospital Corporation |
Genetic Risk Predictor
|
|
US20190341125A1
(en)
|
2017-07-12 |
2019-11-07 |
The General Hospital Corporation |
Inflammatory bowel disease polygenic risk score
|
|
US20190330698A1
(en)
|
2017-07-12 |
2019-10-31 |
The General Hospital Corporation |
Diabetes polygenic risk score
|
|
US20190345566A1
(en)
|
2017-07-12 |
2019-11-14 |
The General Hospital Corporation |
Cancer polygenic risk score
|
|
US11680296B2
(en)
|
2017-10-16 |
2023-06-20 |
Massachusetts Institute Of Technology |
Mycobacterium tuberculosis host-pathogen interaction
|
|
WO2019199684A1
(en)
|
2018-04-09 |
2019-10-17 |
The Regents Of The University Of Michigan |
Methods and systems for biocellular marker detection and diagnosis using a microfluidic profiling device
|
|
MX2020013994A
(es)
|
2018-06-22 |
2021-05-27 |
Bluestar Genomics Inc |
Análisis de hidroximetilación de muestras de ácido nucleico sin células para asignación de tejido de origen, y métodos relacionados de uso.
|
|
US20210285050A1
(en)
|
2018-07-06 |
2021-09-16 |
United States Government As Represented By The Department Of Veterans Affairs |
Pde3b variants
|
|
WO2020010186A1
(en)
*
|
2018-07-06 |
2020-01-09 |
Derek Klarin |
Pcsk9 variants
|
|
JP2022507958A
(ja)
*
|
2018-11-27 |
2022-01-18 |
ノバルティス アーゲー |
代謝障害の治療用のプロタンパク質転換酵素サブチリシン／ケキシン９型（ｐｃｓｋ９）阻害薬としての環状四量体化合物
|
|
EP3969620B1
(en)
|
2019-05-17 |
2025-06-25 |
Regeneron Pharmaceuticals, Inc. |
Genome-based methods for reducing cardiovascular risk
|
|
CN113874020A
(zh)
|
2019-05-22 |
2021-12-31 |
基诺富公司 |
使用曲美替尼和标志物治疗神经退化性疾病的给药方法和剂量方案
|
|
US20200368239A1
(en)
|
2019-05-22 |
2020-11-26 |
Genuv Inc. |
Treatment of amyotrophic lateral sclerosis using trametinib
|
|
WO2021058597A1
(en)
|
2019-09-24 |
2021-04-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of determining whether a subject is at risk of developing arterial plaques
|
|
US20210113536A1
(en)
|
2019-10-21 |
2021-04-22 |
United States Government as Represented by the Department of Veteran Affairs |
Methods and compositions for detecting and treating venous thromboembolism
|